Abstract Background Great progress has recently been made in the treatment of metastatic renal cell carcinoma, including the introduction of nivolumab, an immune checkpoint inhibitor. Despite promising results, this treatment brings a completely new spectrum of adverse events, distinct from those experienced with small-molecule kinase inhibitors. Neurologic immune-related adverse events may be serious and potentially life-threatening complications requiring immediate immunosuppressive therapy. Only a few cases of immune-related encephalitis induced by checkpoint inhibitors have been described and the data regarding the management of this serious adverse event are limited. Case presentation We report the case of a 63-year-old white man with ...
The use of immune checkpoint inhibitors including ipilimumab and nivolumab has expanded for several ...
The use of immune checkpoint inhibitor (ICI) therapy in the treatment of solid organ malignancies is...
Background: Immune checkpoint inhibitors are changing the landscape of oncologic treatment as they a...
Immune checkpoint inhibitors are antibodies, which enhance cellular and humoral immune responses and...
Immune checkpoint inhibitors have improved patient survival outcomes in a variety of advanced malign...
Recurrent clear cell ovarian carcinoma is a difficult to treat condition and early trial data has su...
INTRODUCTION: Immune checkpoint inhibitors have taken an important place in the treatment of differe...
Background Despite unprecedented efficacy across multiple tumor types, immune checkpoint inhibitor t...
Immune checkpoint inhibitors (ICPis) have revolutionised the treatment of melanoma by significantly ...
Abstract Background Immune checkpoint blockade is developed as standard treatment for non-small cell...
The treatment of cancer is a rapidly evolving field. As more chemotherapeutic agents become availabl...
Checkpoint inhibitors have been reported to cause varied autoimmune manifestations including autoimm...
Introduction: Immunotherapy using checkpoint inhibitors has revolutionized the treatment of cancer, ...
Background: With the expanding indications and thus broader use of immune checkpoint inhibitors, cli...
In recent years, advances in the understanding of the regulatory mechanisms of the immune system has...
The use of immune checkpoint inhibitors including ipilimumab and nivolumab has expanded for several ...
The use of immune checkpoint inhibitor (ICI) therapy in the treatment of solid organ malignancies is...
Background: Immune checkpoint inhibitors are changing the landscape of oncologic treatment as they a...
Immune checkpoint inhibitors are antibodies, which enhance cellular and humoral immune responses and...
Immune checkpoint inhibitors have improved patient survival outcomes in a variety of advanced malign...
Recurrent clear cell ovarian carcinoma is a difficult to treat condition and early trial data has su...
INTRODUCTION: Immune checkpoint inhibitors have taken an important place in the treatment of differe...
Background Despite unprecedented efficacy across multiple tumor types, immune checkpoint inhibitor t...
Immune checkpoint inhibitors (ICPis) have revolutionised the treatment of melanoma by significantly ...
Abstract Background Immune checkpoint blockade is developed as standard treatment for non-small cell...
The treatment of cancer is a rapidly evolving field. As more chemotherapeutic agents become availabl...
Checkpoint inhibitors have been reported to cause varied autoimmune manifestations including autoimm...
Introduction: Immunotherapy using checkpoint inhibitors has revolutionized the treatment of cancer, ...
Background: With the expanding indications and thus broader use of immune checkpoint inhibitors, cli...
In recent years, advances in the understanding of the regulatory mechanisms of the immune system has...
The use of immune checkpoint inhibitors including ipilimumab and nivolumab has expanded for several ...
The use of immune checkpoint inhibitor (ICI) therapy in the treatment of solid organ malignancies is...
Background: Immune checkpoint inhibitors are changing the landscape of oncologic treatment as they a...